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Alemtuzumab is a monoclonal antibody, which was recently approved for the treatment of active relapsing
remitting multiple sclerosis. Its main mechanism of action is based on targeting CD52, an antigen of unknown
function which is found on B and T lymphocytes, leading to depletion followed by repopulation of these cells. The
high efficacy of Alemtuzumab in controlling relapsing remitting MS has been shown in several clinical trials. This
new therapy approach is associated with a specific side effects profile requiring regular longterm monitoring. The
most important side effects are infusion-associated reactions, a slight increase of infections as well as autoimmune
events in almost one third of treated patients.
Based on two years of clinical experience in Germany, this review covers the first steps with the careful patient
selection to be treated with Alemtuzumab over the preparation steps and the infusion courses up to the longterm
monitoring after Alemtuzumab treatment.Background
In September 2013, Alemtuzumab was approved in
Europe as an additional therapeutic option for active
relapsing-remitting Multiple Sclerosis (RRMS). Since its
synthesis in the early eighties as the first humanized
monoclonal antibody, Alemtuzumab therapeutic poten-
tials were explored for many diseases (eg. Graft versus
host disease, transplantation, vasculitis, rheumatoid arth-
ritis, immunologically mediated cytopenia) [1, 2]; it is
the first depleting monoclonal antibody which was li-
censed for the treatment of RRMS. The mechanism of
Alemtuzumab differs from immunmodulating and other
immunosuppressive treatments in its fundamental ap-
proach, which consists of at least two courses of lympho-
cyte depletion followed by cellular repopulation. The
reconstitution of lymphocytes is thought to be of particu-
lar importance not only for the beneficial clinical effects,
but also for the long-term side effects [3]. Alemtuzumab is
introducing a new therapeutic concept of an induction-
like treatment strategy, but without the need of a mainten-
ance treatment in the follow up in most of the treated
patients. Such concepts are till now not well established in
our clinical practice. Furthermore, other highly efficacious* Correspondence: Tjalf.Ziemssen@uniklinikum-dresden.de
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are available. No clinical trials have directly compared
Alemtuzumab with these medications making the clinical
decision not straight forward.
Although the role of Alemtuzumab in RRMS was
investigated in three active-controlled clinical studies
[4–6], using it in clinical practice can be quite challen-
ging as several questions are still to be answered: how to
define patients who will most likely profit from Alemtu-
zumab? Where does Alemtuzumab stand in MS treat-
ment scenario? And then if Alemtuzumab is to be given,
how should we switch patients from other specific MS
treatments to Alemtuzumab? What other MS medica-
tions could be given following Alemtuzumab? How
could the infusion management be optimized? Which
side effects can be expected and how should they be
handled? What is the most applicable monitoring strat-
egy in clinical practice?
The aim of this review is to summarize our experience
with Alemtuzumab in clinical practice of the last two
years following a structured approach starting with treat-
ment selection followed by preparation and infusion
management up to the longterm monitoring.
The innovative treatment concept of alemtuzumab
Alemtuzumab is a monoclonal antibody that selectively
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of T- and B-cells and other cell populations but not on
the hematological precursors [8]. Alemtuzumab infusion
results in rapid depletion of the CD52 positive cells [9],
leading to lymphopenia, which lasts for several years
[10]. While B-cells recover relatively quickly within a
range of 3–8 months, the repopulation of T cells occurs
more slowly, as it needs up to 3 years and in another
study up to 60 months for CD4+ and 30 months for
CD8+ T cells in average [11, 12]. The experimental data
using humanized CD52 mice have shown, that the de-
pletion of lymphocytes upon anti-CD52 treatment was
predominant in peripheral circulation, while the number
of those cells was clearly less affected in spleen, thymus,
bone marrow and lymph nodes [13, 14]. This may repre-
sent an explanation for the unexpected low rate of infec-
tions in patients receiving Alemtuzumab. As mentioned
before, the depletion of CD52-positive cell is followed by
a recovery phase that can vary between treated patients.
However, it was shown that different repopulation kinet-
ics among patients was not able to predict the risk of
MS reactivation [14–16].
This process is considered as part of the reprogramming
of the dysregulated immune system. Some authors suggest
that the observed prolonged effect of Alemtuzumab lies in
the slow reconstitution of T lymphocytes after the initial
depletion, and not in the depletion itself [3].
The radical approach of Alemtuzumab which leads to its
prolonged therapeutical effect is actually also associated
with the well-described side effects. In addition to the
infusion-associated reactions (IAR), which will be described
in more details later, the increased incidence of antibody-
mediated autoimmune diseases upon Alemtuzumab ther-
apy is remarkable [17]. Taking into consideration the previ-
ously described mechanism of immune cells depletion and
the potential side effects, the need arises to find appropriate
criteria that are useful for patient selection.
No biomarker to detect predisposition for secondary
autoimmunity has been found yet. IL-21 was previously
described as a promising candidate but these results
could not be reproduced in another following study,
which was attributed to the use of different kits [18, 19].
Different treatment strategies
Alemtuzumab therapy consists of two courses with
12 months in between. In spite of this non-frequent inter-
mittent administration of the medication, this approach
guarantees a long-term stabilization of the disease activity
and to achieve the therapeutic effect, keeping in mind that
Alemtuzumab infusions should take place under close
monitoring. Until now, all available highly-efficacious
therapies as Natalizumab and Fingolimod follow a con-
tinuous treatment strategy. After stopping these drugs,
disease activity is returning or even overshooting as it hasbeen described for Natalizumab [20, 21] and also even in
fewer cases for fingolimod [22–25]. On the other side,
treatment switches are easier to perform if a more or less
reversible treatment as Fingolimod or Natalizumab is ap-
plied. The disadvantage is that the use of other treatment
approaches after Alemtuzumab is more complicated due
to the effects of irreversible depletion and repopulation,
on the other side patient is practically off treatment after
the second Alemtuzumab infusion. The rapid onset of
Alemtuzumab treatment effects can be explained by de-
pletion of both cells of the acquired and innate immune
system, including the impairment in activation as well as
cytokine release [9].
Comparing side effects, Alemtuzumab has specific
windows where side effects are increased specifically
(IARs during infusion, infections directly after infusion,
secondary autommunity with a maximum in the third
year) [26, 27] which is different to risk of adverse events
of eg. Natalizumab presenting an increased PML risk
after a certain treatment duration [28]. In the field of
MS treatment, we have for the first time different treat-
ment strategies with different efficacy and risk profiles
during the treatment duration which should be consid-
ered before treatment is selected (Fig. 1). Alemtuzumab
presents with characteristics of induction treatment al-
though strategy is not correctly defined by the term in-
duction treatment as in the most cases no maintenance
treatment is necessary at least for the 5 year window
after treatment start [29].
Patient selection: who is the right patient for
Alemtuzumab?
According to the European Medicines Agency (EMA),
Alemtuzumab is approved for the treatment of patients with
active RRMS [30], whereas disease activity is defined by clin-
ical and/or imaging criteria. According to the criteria for as-
sessment of MS activity proposed by Lublin and colleagues
[31], a patient with RRMS would be considered as having an
active course if a clinical relapse took place or the brain MRI
showed new Gadolinium-enhancing and/or the increase in
size or number of T2 lesions. MRI monitoring should be
done in regular annual intervals [32]. In the clinical trials,
the disease duration was limited to 5 years in treatment
naïve and to 10 years in pretreated patients [4, 6] probably
because Alemtuzumab was not able to cause improvement
in SPMS patients in a small pivotal study [11]. So in our
opinion, the benefit of the patients regarding Alemtuzumab
treatment is optimal if significant inflammatory signs are
present clinically and by MRI. So Alemtuzumab is not indi-
cated for patients who do not show any disease activity, and
it is also not considered as a standard alternative for patients
who are stable on current therapy.
It should be emphasized that for MS patients with
high disease activity, highly efficacious therapy options
Fig. 1 Comparison of different highly efficacious RRMS therapy strategies Alemtuzumab (right), and Natalizumab (left). The upper diagrams show
the adverse effects, which happen usually within specific time windows, the lower diagrams the clinical efficacy
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“window of opportunity” [33]. That implies that the opti-
mal timing would be in the presence of significant clin-
ical and MRI inflammatory activity without significant
disability [34]. Therapeutical efficacy of Alemtuzumab is
most prominent in early stages of disease by reducing
inflammatory activity to counteract the development
and accumulation of disability [11, 35]. Patients present-
ing with an EDSS value up to 3–4 still potentially have
predominant inflammatory processes, while irreversible
damage is increasingly assumed to be associated with
higher EDSS values [36]. Accordingly, Alemtuzumab is
most appropriately to be used before an EDSS score of 4
is reached. This should not be interpreted that patients
with higher EDSS scores can not benefit from treatment
with Alemtuzumab, as the indication should be consid-
ered based on clinical and/or radiological disease activity
Actually in some patients Alemtuzumab is used as “last
option” treatment as many treatments before have failed.
The efficacy of Alemtuzumab as last option treatmentstrategy has to be investigated by defined cohort or real
world studies [37, 38].
In addition to the disease activity as a determining
factor in the therapeutic decision, other factors, such
as patient personality and cognitive skills, should be
taken into consideration. Because of necessary long-
term monitoring patient’s discipline is demanded, as
Alemtuzumab treatment is potentially associated with
severe adverse effects which have to be identified
early [39].
Keeping in mind that different forms of MS are medi-
ated by different pathological processes, possibly impli-
cating different therapeutical approaches, the diagnosis
and classification of MS should be definitely confirmed.
Neuromyelitis optica (NMO) which was long been con-
sidered as a special form of MS, is associated with differ-
ent etiology. Alemtuzumab is not considered as a first
line treatment option in this disease, as several case re-
ports showed a worsening of NMO under Alemtuzumab
treatment [40–42].
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of Alemtuzumab directly with other highly active therap-
ies, such as Natalizumab or Fingolimod, the clinical
decision to choose one of the above mentioned medica-
tions is largely based on other factors. That would in-
clude on top of the list the potential side effects of each
drug versus the expected benefit. Additionally the rela-
tive and absolute contraindications should be carefully
assessed to choose the most suitable drug. For example,
patients with positive anti-JCV status represent high-risk
group for PML development on longterm Natalizumab
treatment [43]. For female patients in child-bearing age,
Alemtuzumab can be the choice, but the it should be
planned 4 months after the last infusion [44].
There are relative and absolute contraindications for
Alemtuzumab treatment, which should be taken into
consideration (Table 1).
Patient preparation: pretreatment
The strategy how to initiate the treatment with
Alemtuzumab depends on pretreatment status of the pa-
tient (Fig. 2). In treatment-naïve MS patients, an immediate
start of Alemtuzumab is possible. Moreover, Alemtuzumab
treatment accompanied with high dose steroids can itself
even be used as an acute relapse treatment. Direct
switching from Interferon-beta or Glatiramer Acetate to
Alemtuzumab is also possible without any specific washout
period if no relevant laboratory abnormalities (for example
lymphocytopenia) are present. In case of Teriflunomide
and Dimethylfumarate, it is advised to wait at least one
month before Alemtuzumab administration, as it isTable 1 Absolute and relative contraindications of
Alemtuzumab
Absolute contraindication
Hypersensitivity to the active substance, or to any of the excipients.
Severe active infections. Additionally, this drug should not be used in
the presence of active chronic or recurrent bacterial or viral infections,
such as TB, HCV. HBV or HIV.
Pregnancy or lactation.
Relative contraindication
Blood coagulation disorders such as dysfibrinoginemia, factor IX
deficiency, hemophilia, von Willebrandt disease, or anti-coagulation
therapy.
Significant infection liability, such as aspiration susceptibility or frequent
urinary tract infection.
Malignant diseases in the patient history, which is not curatively treated.
Thrombocytopenia.
Negative Varicella-zoster IgG status
Severe liver or kidney insufficiency
Children under 18 years of agerequired that the levels of lymphocytes are within normal
range (>1.5 GPt/l). It is also recommended to accelerate
Teriflunomide elimination by Cholestyramine application
and determine its blood concentration before the Alemtu-
zumab start. Patients stopping Fingolimod should have re-
covered to physiological absolute lymphocyte counts as
well which is an important pharmacodynamics parameter
considering the mechanism of action of Fingolimod [45].
In patients switching from Fingolimod, we are not as strict
with a recovered absolute lymphocyte count (>1.0 GPt/l)
as with Dimethylfumarate (>1.5 GPt/l) as Fingolimod is
only affecting lymphocyte redistribution between lymph-
oid tissues and blood.
Prior therapy with Natalizumab represents a special
situation as the switching protocol depends on the actual
PML risk which is closely linked to the JCV status and
treatment duration [28]. The challenge is to find a way be-
tween returning disease activity after Natalizumab and
PML risk. Because of the irreversible and acutely immu-
nosppressive mechanism of action of Alemtuzumab, a car-
ryover PML after natalizumab treatment which has been
described occurring even up to 6 months after Natalizu-
mab cessation has to be excluded before treatment start
[46, 47]. So if there is only a low PML risk which means
treatment duration with Natalizumab less than 2 years
and/or negative anti-JCV antibodies, a washout period be-
tween two and three months is considered sufficient until
pharmacodynamic effects of Natalizumab have disap-
peared. MRI and possibly CSF analysis should be per-
formed as part of the work up as described later. For
patients with higher PML risk (JCV antibody positive and
treatment duration > 2 years) we recommend a stepwise
approach. 3 months after last infusion first MRI should be
performed to exclude PML and monitor return of disease
activity. If no MRI activity is present, follow up MRI will
be performed 4 weeks later which will be repeated until
6 months. If there is MRI activity (or clinical activity)
present, CSF analysis with JCV DNA and cell count
should be performed before Alemtuzumab is started. This
procedure has been applied many times in our clinical
practice and can avoid return of clinical activity and makes
PML much more unlikely. This means that a strict
6 months washout period cannot be applied in all PML
high risk patients on Natalizumab. It is crucial to imple-
ment an individual approach for the switch of natalizumab
to Alemtuzumab. As irreversible, cell depleting therapy, a
carry over of a Natalizumab-associated PML has to be
avoided in potential Alemtuzumab patients. In our hands,
identifying patients with MRI activity was mostly sufficient
to avoid clinical rebound activity as Alemtuzumab demon-
strates a rapid onset of action. After immunosuppressive
therapies, such as Azathioprine, Cyclosporine A, Mitoxan-
trone or Cyclophosphamide, which are rarely used now-
adays, wash-out period of 3–6 months is necessary in
Fig. 2 Recommended protocols for switching to Alemtuzumab, regarding different pretreatments. Special attention should be paid for patients
who were previously treated with natalizumab, two different protocols are suggested depending on the individual PML risk
Table 2 Recommended lab testing before Alemtuzumab
treatment/retreatment
Differential blood count, and optionally an immune status depending
on the pretreatment and on the number of lymphocytes
Liver panel including SGOT, SGPT, GGT, bilirubin
Kidney panel including Creatinine, GFR
Thyroid panel including TSH, T3, T4
Infection status including Syphilis, VZV, HIV, hepatitis serology, TB test
(eg. Quantiferon test)
Coagulation panel including INR, PTT
Urine panel including quantitative urinalysis by sediment microscopic
analysis
HPV screening and pregnancy test in women
Infection screening panel including CRP, BSG
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theless patients after immunosuppressive pretreatment
are not the ideal patients although case reports have re-
ported beneficial effects [37].
In general, it should be kept in mind that these recom-
mendations are general. In everyday clinical practice we
are confronted with special individual patient cases that
may require deviation from the general recommenda-
tions. These adjustments are justified depending on the
individual disease activity and progression, and it is ad-
visable to document the reason for the different ap-
proach appropriately [48].
Patient preparation: preparatory steps
Taking into consideration the well-known side-effects and
contraindications of Alemtuzumab, a detailed patient his-
tory and physical examination should be performed to ex-
clude possible contraindications. Effective treatment should
be given in case of acute infections. It is required to wait
until the infection is cured before going on with the Alem-
tuzumab infusion. On the other hand, chronic Infections
such HBV, HCV, TBC and syphilis (except HIV) do not
represent absolute contraindications, but their presence de-
mands additional carefulness. An active infection should be
excluded. In case of a positive quantiferon test, active TBC
has to be excluded by chest X-ray and prophylactic treat-
ment with Isoniacid for at least half a year has to be started
before Alemtuzumab treatment can begin 6–8 weeks later[49]. Neoplasms, which are considered as relative contra-
indication, should be cured before initiating Alemtuzumab
treatment. Recommended lab tests before starting treat-
ment with Alemtuzumab are described in Table 2. This
workup should be done before every Alemtuzumab infu-
sion later on.
MRI of the complete neuroaxis (not older than three
months) should be performed as documentation for base-
line status before Alemtuzumab start. All the above-
mentioned tests should be accomplished and managed be-
fore the first treatment course; and these safety investiga-
tions should be repeated prior to the commencement of
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ments regarding lymphocyte or leukocyte cell counts which
have to be reached before second Alemtuzumab course.
Women with childbearing potential should be informed
to use an effective contraception during treatment phase
and four months thereafter.
Especially for patients who have a history of neither
chicken pox infection nor of previous vaccination
against Varicella-Zoster virus, it is obligatory to measure
its antibodies level before initiating Alemtuzumab treat-
ment. We recommend VZV testing in all patients before
Alemtuzumab application. For those who are VZV antibody
negative the vaccination should be given, followed by meas-
uring the VZV antibody titer four to six weeks after VZV
vaccination. As vaccinations may be complication by the
depleting-repleting mechanism of action vaccination status
should be checked and necessary vaccinations should be
performed before first Alemtuzumab application.
Before first Alemtuzumab treatment, patients should
be informed about potential side effects and the need for
regular monitoring which is mandatory for a beneficial
risk-beneftit ratio of Alemtuzumab.
Alemtuzumab infusion management
Treatment with Alemtuzumab consists of at least two
courses of infusion therapy with twelve months in be-
tween. During the first course (“the induction course”)
the monoclonal antibody is intravenously infused over
five consecutive days with the recommended dose of
12 mg/day. Out of practical reasons it is useful to start
the treatment course on Monday to avoid infusions dur-
ing weekends. One year later, Alemtuzumab is infused in
a second course of treatment (“the maintenance course”)
over three consecutive days. Between the two treatment
courses no immunomodulatory treatment should be ap-
plied. Shortening the interval between these two courses
is not recommended as there is no experience. To re-
duce the infusion-associated reactions (IAR), a specific
schedule of infusion should be applied (Table 3).
The day before Alemtuzumab infusion, H1 and H2
blockade should be initiated which could be applied be-
yond the infusion week if necessary [30, 50]. An anti-
pyretic, given 30–60 min before infusion, may help to
reduce the infusion reaction.
In addition, a short infusion of methylprednisolone
(1 g) is recommended for the first three days of treat-
ment. Cytokine release and lymphocyte activation could
account for such infusion-associated reactions [51, 52].
Induction of serum cytokines could be due to cross-
linking of NK cells in addition to cell lysis [52]. Pivotal
studies not using standardized infusion procedure and
methylprednisolone pre-treatment demonstrated higher
levels of serum cytokines and significant more IARs after
initial alemtuzumab infusions [51]. Pre-and concomitantmethylprednisolone treatment incorporated into the
standard infusion protocol may attenuate cytokine re-
lease syndrome and help reduce infusion-associated re-
actions to enhance patient tolerance [50]. This protocol
is based on the procedure in pivotal studies. However, in
deviation from this study experience, the steroid infusion
may be adjusted depending on the individual situation
and the patient’s response. This mean extension over
5 days or potential pretreatment one day before Alemtu-
zumab infusion which is actually investigated in a clin-
ical trial. If the Alemtuzumab course could not be
completed over the consecutive 5 days, if the course has
to be interrupted because of eg. acute infection with
fever, the remaining Alemtuzumab infusions should be
performed as soon as possible in the next weeks. In this
case, methylprednisolone should be applied before all
remaining Alemtuzumab infusions.
Alemtuzumab infusion should be started after methyl-
prednisolone infusion. Mixing these preparations is not
allowed, as this can lead to precipitation of the drug. Alem-
tuzumab itself is diluted immediately before the infusion in
100 ml of 0.9 % sodium chloride solution or 5 % glucose so-
lution (chemically stable at 2–8 °C for up to 8 h). Other in-
fusions could be applied using the same intravenous port as
Alemtuzumab, a paravenous infusion is not critical as Alem-
tuzumab is a monoclonal antibody and not a chemotherapy.
The infusion-associated reactions (IAR) occur in up to 90 %
of patients treated with Alemtuzumab [50]. Skin reactions
are observed predominantly. With mild symptoms, symp-
tomatic treatment with anti-histamergic treatments or anti-
pyretics/anti-inflammatory treatments and slower infusion
rate are usually sufficient. In case of severe reactions such as
fever, urticaria, atrial fibrillation, nausea, chest discomfort or
hypotension, the infusion should be stopped immediately.
Because of these potential acute infusion-associated reac-
tions, anaphylaxis therapy should be kept ready although
the reaction to Alemtuzumab is generally not anaphylactic,
so that the infusion can be further continued. The observa-
tion for two hours after the end of the infusion is necessary.
In our hand, monitoring of the patient’s temperature seems
to be an effective method for early detection of an infusion-
associated reaction in everyday practice [30]. It is therefore
recommended to monitor and document the body
temperature every half hour. Heart rate and blood pressure
should also be measured every one hour. In addition to this
reaction, reappearance of old neurological deficits, which oc-
curred in the context of past relapses, can also occur, which
it is caused by the release of cytokines due to cell depletion
in a process similar to Uhthoff effect (Cytokine Uhthoff syn-
drome) [51]. The highest drug level is reached after the last
infusion [53]. However, even if this falls in the next few days,
its effect with regard to lymphocyte depletion goes on, so
that it is still possible to experience reactions related to cells
depletion [9].
Table 3 Recommended infusion protocol
Pre-Infusion Concomitant medication: The evening before the 1st Alemtuzumab infusion for all infusion stages, orally:
– H1 blockade eg. Cetirizine 1-0-1 (non-sedating H1 antihistamine)
– H2 blockade eg Ranitidine 300 mg 1-0-1 (H2 receptor antagonist)
– Herpes prophylaxis eg. Aciclovir 200 mg 1-0-1 (for HSV/VZV prophylaxis; for at least 4 weeks)
Infusion 1st year: infusion 5 days (Mon.-Fri.)
2nd year infusion 3 days (3 consecutive days)
Cardiovascular (BP, heart rate) + Body temperature (1×/30 min) Monitoring
– 1st day of infusion course: Perform pregnancy test in female patients with childbearing potential
– Insertion of peripheral permanent port (can also be used for other medications)
1. 60 min. before Alemtuzumab infusion:
a) Methylprednisolone 1 g i.v. as short infusion at the first 3 infusion days
b) Paracetamol 1 g. i.v. as short infusion at all infusion days
2. Alemtuzumab 12 mg i.v. via infusion pump (12 mg per day on each of 5 (or 3) days), is prepared as ready-to-
use solution supply (volume 112 mL). Storage time of the infusion 8 h after preparation.
- Target infusion period about 4 h (in case of side effects-especially at the start of the infusion-reduction of
the infusion speed)
3. NaCl infusion 100 mL over 30 min (infusion pump), to flush residual medication out of the infusion line
(tube)
Also to note:
– Monitoring until 2 h after infusion
– Drinking adequate liquids (at least 2 l/d)
– Availability of trained physician and medical personnel during the entire period of the infusion
Potential acute adverse
events
1. Anaphylaxia/anaphylactic shock (quite rare)
2. Infusion-associated reactions (IAR):
– Erythema, urticaria, pruritis, (fever, headache, fatigue)
– Intensified neurological symptoms (Uhthoff Phenomenon!)
➔ STOP infusion and inform physician immediately!
➔ Fenistil 1 A (4 mg) i.v.
➔ In case of insufficient effect ➔ 250 mg prednisolone i.v.
Depending on severity of the IAR, continue infusion, but more slowly.
Routine follow-up care 1. Aciclovir 200 mg 1-0-1 for 4 weeks from the first day of the infusion
2. Antihistamine (e.g. cetirizine 1-0-1) for an additional week
3. Paracetamol standby (if headache or fever appear)
First check-up appointment MS centre 4 weeks after infusion.
Procedural measures/follow
up checks
– Adequate infection protection including adjusting diet (no cheese from raw milk, raw fish/raw meat)
– During the infusion course, avoid stomach-irritating foods such as fruit acids, carbonates, sharp or strong-
smelling foods, no sodium glutamate-“bland diet”
– If applicable, safe contraception methods for at least 4 months after the infusion course
– Due to the known potential side effects, the regimen of follow-up check-ups organised and implemented by
the MS centre must be strictly observed
– Patients are instructed to observe a low threshold for making an acute appointment in case of infections. In
this respect, the reduced immune competence and reduced lymphocyte count must be considered,
especially in the first months after infusion, and a complete focus screening must be conducted.
– The patient should be informed of the symptoms of possible side effects (eg. ATP, glomerulonephritis), and
should inform the treating physician of them. An early appointment with the physician should also be made
in case of infection.
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Alemtuzumab treatment is associated with an increased
risk for the development of autoimmune diseases, for this
reason a regular monitoring is indicated to allow for an
early recognition and thereby early treatment of these dis-
eases [10, 17, 19, 54–57]. Most of the autoimmune phe-
nomena have a beneficial prognosis if they are identified
early and anti-inflammatory treatment is started early. So
monthly check-ups should take place up to 48 months
after the last infusion, including a complete differential
blood count to detect the development of Alemtuzumab-
induced thrombocytopenic purpura (ATP) [58, 59]. In
addition, monthly monitoring of serum creatinine levels
and urine tests with microscopy for an early detection of
possible glomerulonephritis are necessary [59]. Thyroid
function test using the TSH value should also be per-
formed every three months. In pregnant patients with spe-
cial interest in thyroid monitoring monthly TSH testing is
recommended [55, 57, 60].
The monitoring does not need to be performed by the
treating neurologist. Good experiences are reported in
terms of the cooperation with general practitioners, who
can perform or arrange for the check-ups. However, it is es-
sential that the treating neurologist ensures that the control
tests are carried out according to previous specifications
and the obtained results are evaluated. Treating neur-
ologist has to organize and supervise monitoring after
Alemtuzumab treatment. Patients should be clearly
informed not to wait for problems to happen, but im-
mediately and regularly communicate with their physician.
Modern communication tools as email reminders, smart-
phone could be nicely implemented in the patient
management [61].Collecting real world data in an alemtuzumab registry
Although the clinical experience with the agent has sub-
stantially increased since market introduction, there are
only few reports yet on the long-term use of the drug in
the routine of physicians and MS centers [10, 16, 44].
That is why real world data about Alemtuzumab data
should be collected as the German non-interventional
long-Term study foR obsErvAtion of Treatment with
Alemtuzumab (TREAT-MS) which is documenting
physician and patient experience in daily clinical practice
for six years [62]. Data for this non-interventional study
will be collected on a widely unselected patient popula-
tion eligible for Alemtuzumab treatment. It is expected
that compared to the clinical studies, patients with more
concomitant diseases and/or more concomitant medica-
tions will be documented. Together with the high pa-
tient numbers and long follow-up period, a substantial
number of patient years will be documented and the op-
tion for relevant subgroup analyses provided [48].For this observational study, a protocol was developed
based on the risk management plan for alemtuzumab.
By participation in the study, physicians are reminded
about the investigations and precautions. The documen-
tation system MSDS3D has been shown to be efficient
to guide physicians through the study procedures and to
collect the relevant information in clinical practice and
for the use in previous non-interventional studies such
as PANGAEA [63]. It interactively collects data, but also
assists neurologists in the execution of complex pro-
cesses required for comprehensive management of MS
patients (Fig. 3a, b) [64–66].
Infections
As infections can be facilitated by cellular depletion of the
adaptive and innate immune system together and infusion-
associated reaction symptoms like fever, headache, and fa-
tigue may mimic infectious signs, routine blood analysis is
usually a suitable tool to identify infectious conditions. But
laboratory monitoring during infusion therapy is not
needed, and it can even be affected by cell depletion-
related artifacts [9]. During the the first infusion week,
rapid cellular depletion and impairment of activation of
different adaptive and innate immune cell subtypes take
place accompanied by marked serum cytokine increases.
Nevertheless, these acute Alemtuzumab-mediated effects
are assumed to lead to several effects observable by stand-
ard blood testing, such as the non-infectious increase in
leukocyte count, CRP, and PCT, which are of particular im-
portance in identification and monitoring of infectious
conditions. Furthermore, transient elevation of liver
enzymes, thrombocytopenia, and TSH modulation are
demonstrated. So we recommend clinicians to be aware of
clinical symptoms and vital data to initiate supportive ana-
lysis rather than standard laboratory testing within the first
alemtuzumab treatment week [9].
In general, patients should also be advised to avoid the
consumption of raw foods such as raw milk products be-
cause of possible contamination with listeria [30]. The
ability of Alemtuzumab to deplete dendritic cells as well
may explain cases of Listeria meningitis linked to the
initial Alemtuzumab infusions [9, 67, 68]. Listeria men-
ingitis infection may be facilitated by immune cell deple-
tion in the adaptive as well as the innate immune
system, possibly by an outburst of a pre-existing, clinic-
ally silent and CD8+ T cell controlled infection due to
cellular depletion and activation blockade. These find-
ings highlight the relevance of certain infections, which
could be promoted by the depletion and blockade of in-
nate immune subsets, that clinicians should be aware of
within the first days after initial Alemtuzumab infusion.
Patients who have acute or chronic infections should not
start with Alemtuzumab therapy. As mentioned above the
presence of acute infections under Alemtuzumab therapy
ab
Fig. 3 a/b The standard protocol for documentation of the different monitoring parameters as displayed on MSDS3D, which enables for
monitoring laboratory, clinical, and radiological progression, as well as planning the next step in approaching patients who showed abnormalities
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Taking into consideration that human papilloma virus in-
fections (including cervical dysplasia) were described, it is
obligatory for female patients to perform an annual HPV-
screening with cervical cytology, especially when no former
HPV vaccination was given.
Due to the observed increased rate of herpes infections,
prophylaxis with acyclovir is recommended [69]. In the
phase 3 clinical studies, this prophylactic regimen was in-
troduced not from the beginning on [4, 6, 59]. But the pa-
tients receiving 200 mg of acyclovir twice daily or an
equivalent for this purpose demonstrated less herpetic in-
fections. Prophylaxis should begin on the first day of each
treatment phase and should be maintained throughout the
course of treatment for at least for 1 month. It should be
noted that acyclovir can cause several immunological phe-
nomena including rash itself, which has to be differentiated
from IARs and could be improved by the transition to a
newer treatments, such as Valacyclovir, as an alternative.
In the approval trials infections were moderately in-
creased in Alemtuzumab group compared with interferon
group, represented mainly by mild to moderate infections
in the upper respiratory tract, gastroenteritis and urinary
tract infections [70]. This is a completely different profile
compared to hematological patients treated by higher doses
of Alemtuzumab demonstrating specific opportunistic in-
fections of immunosuppression [71]. In MS patients, infec-
tions were not prolonged and receded under traditional
medical therapy. Serious or opportunistic infections were
not noticed to be increased. Pre-existing chronic diseases,
such as tuberculosis, can be reactivated. No data are avail-
able regarding reactivation of controlled chronic HBV/
HCV infections. In a recent observation period of 7 years
no change in the malignancy rate has been detected [44].
As the thyroid is carefully investigated because of thyroid
autoimmunity by eg. ultrasound, a rise in the incidence of
thyroid papillary carcinoma diagnosis may be the conse-
quence suggesting overdiagnosis [72].Autoimmune adverse events
In a recent study for long-term safety evaluation an inci-
dence of 48 % for secondary autoimmune diseases was re-
ported [44]. This is attributed to dysregulated B cells,
resulting in secondary autoimmunity [17]. Because of this
high incidence of secondary autoimmune diseases, deter-
mining biomarkers that can predict which patients are
more susceptible to develop secondary autoimmunity is of
high importance. Even though a high value of interleukin
21 at baseline could successfully predict the occurrence of
autoimmune diseases in Alemtuzumab treated patients, it
is inadvisable to rely on these values when taking the treat-
ment decision, because of problems related to the confirm-
ation of results by the currently available kits [18, 19]. Anoverview about the lab testing as part of the risk monitor-
ing plan is demonstrated in Fig. 4.
Thyroid disease
The development of autoimmune thyroid diseases is of
high importance as it can be detected in more than 35 %
of patients treated with Alemtuzumab in the 4 years
after first Alemtuzumab infusion [60]. Both hypo- and
hyperthyroidism may occur, and the development of
Graves’ disease was highly prevalent [55].
The peak of incidence is reported to be in the third year
after the first dose of Alemtuzumab. Most events are of
mild to moderate severity and can respond to conventional
therapies. However, surgical intervention may be needed in
less than 1 % of patients. The occurrence of thyroids side
effects requires careful assessment of the clinical status of
the patient and the necessity of medical and/or surgical
therapies before continuing Alemtuzumab treatment. Ac-
cording to data derived from clinical studies, the baseline
value of anti-TPO antibodies before starting alemtuzumab
could not predict the development of thyroid side effects.
Almost 80 % of patients who manifested with thyroidal
problems after alemtuzumab therapy, showed negative
anti-TPO antibody status at the beginning of the study [60].
Alemtuzumab-induced thrombocytopenia
In addition, Alemtuzumab-induced autoimmune-medi-
ated thrombocytopenia was reported in more than 1 % of
patients, which represents a form of idiopathic
thrombocytopenia (ITP) [26, 58, 73].
Acute ITP has occured in ab to 2 % of the treated pa-
tients in clinical MS-studies within 14–36 months after the
first exposure to alemtuzumab. ATP can manifest clinically
with higher tendency to bruises, petechias, spontaneous
mucosal bleedings (epistaxis, hemoptysis), severe or irregu-
lar menstrual bleeding or symptoms of anemia due to
blood loss including serious hemodynamic complications.
Complete blood count including platelet value should be
performed monthly over at least 48 months after the last
alemtuzumab infusion. The platelet control should be per-
formed weekly in case that platelet count drops to less than
30 % of its initial value or below the normal range, and
hematological consultation should be ordered when the
platelet number is less than 100.000 GPt/l.
Normally the acute treatment of thrombocytopenia is
usually low to high dose corticosteroids, it does not tend
to develop a chronic condition. Reports about continuing
alemtuzumab therapy after the development of ATP are
limited and giving a new alemtuzumab infusion should be
assessed on an individual basis [2].
Nephropathies
Nephropathies and individual cases of Goodpasture’s syn-
drome with renal and pulmonary infection were reported
Fig. 4 Algorithm for monitoring patients after alemtuzumab infusion regarding secondary autoimmune side effects
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anti-glomerular basement membrane (anti-GBM) disease,
occured in 0.3 % of the patients in clinical MS-studies up
to 39 months after the last administration of Alemtuzumab.
These cases were early recognized by clinical and laboratory
control, so that they could follow favorable course after ef-
fective treatment. The development of anti-glomerular
basement membrane (anti-GBM) disease without suitable
monitoring had led to renal failure, which in case of delayed
treatment led to dialysis and/or kidney transplantation.
Such side effects can be detected by laboratory monitoring
through the presence of hematuria, proteinuria and/or cre-
atinine elevation. Consequently, an urgent specialized
nephrological consultation will be necessary.
Vaccinations
The efficacy of vaccines during and closely after
Alemtuzumab application can be limited. That is why
it is recommended to check the success of the vacci-
nations by determining their respective titers. The use
of attenuated living vaccination should be avoided.
Patients should fulfill the vaccination requirements at
least six weeks before starting the Alemtuzumab ther-
apy. It should be emphasized that for patients treated
with Alemtuzumab the flu-vaccine should be delayed
at least six months after the last infusion; however
this vaccination can be repeated in case the first
vaccination was not efficient.One pilot study showed that for patients treated with
Alemtuzumab the humoral immunological response
after different vaccinations was not different from that
detected in respective controls [6, 75], implying that the
immune competence is restored after lymphocytes de-
pletion induced by Alemtuzumab therapy. This is in line
with the data derived from clinical studies which dem-
onstrated low incidence of opportunistic infections fol-
lowing Alemtuzumab infusions. However this study was
small and only 5 patients were vaccinated within the first
6 months after Alemtuzumab [16, 76, 77].
Moreover different studies suggested that the long
lasting lymphopenia is neither associated with higher in-
cidence of infections nor with higher activity of MS
compared with accelerated lymphocyte reconstitution
[12, 15, 78].
Pregnancy
No safety data are available till now regarding the poten-
tial influence of Alemtuzumab on male fertility. The
concerns regarding potential effect on fertility remains
not well investigated, as the target antigen CD52 is also
found in the tissues of the reproductive system.
Alemtuzumab is contraindicated during pregnancy and
lactation, as animal studies have shown reproductive tox-
icity because Alemtuzumab, as well as human immuno-
globulins, can cross the placenta. The same applies during
lactation as they can be transferred by breast milk, and
Hassoun et al. Multiple Sclerosis and Demyelinating Disorders  (2016) 1:10 Page 12 of 14the risk to the infant is unknown. Additionally, the in-
creased incidence of autoimmune diseases such as thyroid
disease, particularly by the use of Alemtuzumab in women
of childbearing age represents potential concern [79].
The development of autoimmune diseases had been
observed during the study period within a maximum in
the third year after first infusion followed by a decrease
in risk [44]. So it makes sense to plan for pregnancy ei-
ther after this period has passed or before the third year
which means 4 months after the second infusion, and
then profit from the prolonged high efficiency without
the need for additional medication.
Treatment following the 2 Alemtuzumab courses
The majority of MS patients treated with Alemtuzumab
do not need additional Alemtuzumab infusions or differ-
ent MS treatments in the first 5 years after Alemtuzu-
mab treatment. In a recent analysis for ECTRIMS 2015,
68 % of CARE-MS1 and 60 % of CARE-MS2 have not
received additional Alemtuzumab infusions. 22.1 % resp.
8.0 % of CARE-MS1 and 28.8 % resp. 9.9 % of CARE-
MS2 patients have received one resp. two Alemtuzumab
retreatments. In both clinical trials, the threshold for
Alemtuzumab retreatment was quite low with one re-
lapse activity or two new T2 lesions resp. one new Gd +
lesion in the follow up MRI. If the treatment strategy of
Alemtuzumab has been selected after careful consider-
ation, this selected strategy should be generally main-
tained which means that retreatments should be applied
at least once or twice if needed. Every retreatment
should be accompanied with careful consideration about
retreatment, disease activity, response to Alemtuzumab
and additional treatment options. If the patient seems to
be an Alemtuzumab-non-responder, alternative treat-
ment strategies should be considered as eg. Fingolimod
or B-cell depleting therapies.
In the clinical trials, 2.3 % resp. 7.6 % of the CARE-MS 1
resp. 2 patients have been treated with other MS treatments
in the first 5 years after Alemtuzumab start. The majority
of these 96 out of 1496 patients used baseline medication
(interferon and GA), 10 % each were treated with Fingoli-
mod and Natalizumab. Switching after Alemtuzumab to
Interferon-beta or Glatiramer Acetate can be done quite
quickly after the last Alemtuzumab infusion after excluding
relevant lymphopenia especially for interferon treatment.
There is not a lot of experience with the new oral medica-
tions Teriflunomide and Dimethylfumarate. Especially with
Dimethylfurmarate, the previous immunosuppression with
Alemtuzumab has to be considered. By switching to Natali-
zumab it should be kept in mind that Alemtuzumab leads
to significant long-lasting changes in the adaptive immunity
cells. As Alemtuzumab works as an immunosuppressive,
changing to Natalizumab is associated with higher risk for
PML development especially in patients with positive JCVantibodies. The better treatment option of highly active MS
treatments which has already been used in our center is
Fingolimod. Because of the individually very different pro-
longed effect of Alemtuzumab on the adaptive immunity, it
is not possible to give a general waiting period after the last
Alemtuzumab infusion. A complete immune status can be
helpful including differential blood count, CD4+ T cells,
CD8+ T cells, B cells, NK cells.
Conclusions
Alemtuzumab is a highly efficacious disease-modifying ther-
apy which offers a new treatment principle for the treatment
of relapsing-remitting MS. It shows clear benefits on re-
lapses, disability outcomes, and freedom from clinical disease
and magnetic resonance imaging activity. Infusion-associated
reactions are common with Alemtuzumab, but rarely ser-
ious. Infection incidence was elevated with Alemtuzumab in
clinical studies; most infections were mild or moderate in se-
verity. Autoimmune adverse events occurred in approxi-
mately a third of patients, manifesting mainly as thyroid
disorders, and less frequently as immune thrombocytopenia
or nephropathy. A comprehensive monitoring program last-
ing at least 4 years after the last alemtuzumab dose allows
early detection and effective management of autoimmune
adverse events. Further experience with alemtuzumab in the
clinic will provide needed long-term data.
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